BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3366165)

  • 1. Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.
    Langner B; Lemmer B
    Eur J Clin Pharmacol; 1988; 33(6):619-24. PubMed ID: 3366165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects.
    Fujimura A; Kumagai Y; Sugimoto K; Nakashima H; Kajiyama H; Ebihara A; Ohashi K
    Eur J Clin Pharmacol; 1990; 38(2):133-7. PubMed ID: 2338109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.
    Lemmer B; Scheidel B; Blume H; Becker HJ
    Eur J Clin Pharmacol; 1991; 40(1):71-5. PubMed ID: 2060550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of an interaction between propranolol and sumatriptan.
    Scott AK; Walley T; Breckenridge AM; Lacey LF; Fowler PA
    Br J Clin Pharmacol; 1991 Nov; 32(5):581-4. PubMed ID: 1659437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.
    Bauer LA; Murray K; Horn JR; Opheim K; Olsen J
    Eur J Clin Pharmacol; 1989; 37(3):257-60. PubMed ID: 2612540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronopharmacokinetics and cardiovascular effects of nifedipine.
    Lemmer B; Nold G; Behne S; Kaiser R
    Chronobiol Int; 1991; 8(6):485-94. PubMed ID: 1799930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers.
    Vanakoski J; Seppälä T
    Eur J Clin Pharmacol; 1995; 48(2):133-7. PubMed ID: 7589027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects.
    Shiga T; Fujimura A; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1993; 44(5):489-92. PubMed ID: 8359189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.
    McCourty JC; Silas JH; Tucker GT; Lennard MS
    Br J Clin Pharmacol; 1988 Mar; 25(3):349-57. PubMed ID: 3358897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation.
    Marino MR; Dey M; Garg DC; Jallad NS; Dorick DM; Martinez JJ; Weidler DJ
    J Clin Pharmacol; 1987 Nov; 27(11):885-91. PubMed ID: 3429696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol.
    Ohashi K; Ebihara A; Kondo K; Usami M
    Arzneimittelforschung; 1984; 34(4):507-12. PubMed ID: 6378211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral propranolol in normal subjects.
    LeWinter MM; Crawford MH; Karliner JS; ORourke RA
    Clin Pharmacol Ther; 1975 Jun; 17(6):709-12. PubMed ID: 1139862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
    Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R
    Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol.
    Garg DC; Jallad NS; Mishriki A; Chalavarya G; Kraml M; Fencik M; Weidler DJ
    J Clin Pharmacol; 1987; 27(5):390-6. PubMed ID: 3693583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: Hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels.
    Stoschitzky K; Lindner W; Egginger G; Brunner F; Obermayer-Pietsch B; Passath A; Klein W
    Clin Pharmacol Ther; 1992 Apr; 51(4):445-53. PubMed ID: 1563214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol.
    Bendtsen F; Henriksen JH
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():139-45. PubMed ID: 2550636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.
    Williams FM; Leeser JE; Rawlins MD
    Br J Clin Pharmacol; 1986 Sep; 22(3):301-8. PubMed ID: 3768242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.
    Murdoch DL; Thomson GD; Thompson GG; Murray GD; Brodie MJ; McInnes GT
    Br J Clin Pharmacol; 1991 Mar; 31(3):323-32. PubMed ID: 2054272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency.
    Ahmad AM; Hopkins MT; Weston PJ; Fraser WD; Vora JP
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):431-7. PubMed ID: 11966735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol].
    Telatyńska-Smieszek B; Wójcicki J; Droździk M; Gawrońska-Szklarz B; Sulzyc-Bielicka V; Sterna R
    Pol Arch Med Wewn; 2004 Jan; 111(1):45-51. PubMed ID: 15088420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.